What is stem cell?

A stem cell is a cell that has the ability to divide for indefinite periods, throughout the life of the organism. Under the right conditions or having received the right signals stem cells have the potential to develop into mature cells that have characteristic shapes and specialized functions, such as heart cells, skin cells, or nerve cells.

Why are stem cells so important?

Our cells can be damaged or killed in the result of injury or illness. When it happens, stem cells are activated to repair damaged tissue. They are also involved in the replacement of other cells when they die naturally. Thus, stem cells keep us healthy and prevent our premature aging acting.

What is the therapeutic effect of stem cells?

The therapeutic effect of stem cells is achieved due to their ability to differentiate and transdifferentiate into tissue-specific cells, to fuse with the resident cells, to secrete a wide array of paracrine factors in order to stimulate the survival and functional recovery of the resident cells or to regulate the local microenvironment or immune response.

Conditions to stem cell therapy

What cell products do we cultivate?

  • MSC (Mesenchymal stem cells) from adipose tissue (allogeneic, autologous)
  • MSC from bone marrow (allogeneic, autologous)
  • MSC from umbilical cord (allogeneic, autologous)
  • MSC from placenta (allogeneic, autologous)
  • MSC from endometrium (autologous)
  • MSC from dental pulp (allogeneic, autologous)
  • MSC-neural crest derivatives (MSC-NCD) from hair follicle (allogeneic, autologous)
  • HSC (Hematopoietic stem cells) from bone marrow (allogeneic, autologous)
  • HSC from peripheral blood (autologous)
  • HSC from umbilical blood (allogeneic, autologous)
  • HSC from placenta (allogeneic, autologous)
  • Dermal fibroblasts (autologous)
  • Dermal fibroblasts (autologous) with increased content of myofibroblasts
  • Fibroblasts from umbilical cord (allogeneic)
  • Fibroblasts from umbilical cord (allogeneic) with increased content of myofibroblasts
  • Dermal fibroblasts (autologous) combined with fibroblasts from umbilical cord (allogeneic)
  • Keratinocytes (autologous)
  • Periosteal cells (autologous)
  • Autologous mononuclear cells
  • Endothelial progenitor cells (EPC) from peripheral blood (autologous)
  • EPC from cord blood (autologous)
  • Bone demineralized chips

Sources of cell selection

Placental tissue
Endometrium
Umbilical cord
Cord blood
Peripheral blood
Adipose tissue
Bone marrow
Dental pulp
Hair follicle
Punch biopsy of the dermis

Indications to stem cell therapy

Prevention program for comprehensive improvement of the organism for patients aged over 40

  • Multiple sclerosis
  • Acute disseminated encephalomyelitis
  • Amyotrophic lateral sclerosis
  • Cerebral palsy
  • Organic brain damages
  • Conditions after traumatic brain injuries
  • Conditions after spinal cord injuries
  • Autism spectrum disorders
  • Apallic syndrome
  • Dyscirculatory encephalopathy
  • Consequences of acute disorders of cerebral circulation
  • Alzheimer’s disease
  • Parkinson’s disease
  • Macular dystrophy
  • Optic nerve dystrophy
  • Optic nerve atrophy
  • Pigmentary retinopathy
  • Diabetic retinopathy
  • Compensated glaucoma
  • Stargardt’s macular dystrophy
  • As a part of complex treatment of multiple sclerosis
  • Arthrosis and postoperative conditions of the joints
  • In case the patient is not mentally ready to replace the joint with an endoprosthesis
  • Chronic and acute damages of articular cartilage
  • Aseptic necrosis, Koenig’s disease
  • Fractures of bones that do not grow together for a long time and false joints
  • Chronic tendon inflammation
  • Chronic pain around the joints
  • Rough postoperative and post-traumatic scars
  • Vitiligo
  • Trophic skin ulcers
  • Diabetic foot
  • Erectile dysfunction
  • Male infertility

Thin and non-receptive endometrium

  • Atrophy of the alveolar bone
  • Parodontosis
  • Replacement of dental defects with implants
  • Diabetes mellitus, type II
  • Complications of diabetes mellitus of type I and II
  • Violation of carbohydrate tolerance

Contraindicators to stem therapy

We use an individual approach to each patient of Vitality M&R Center. The doctor always studies the patient’s medical history and develops an individual treatment plan. The presence and absence of contraindications to stem cell therapy is negotiated by the doctor with each patient individually.

  • Malignant neoplasms
  • Critical disorders of blood coagulation system (platelet ≤50×109)
  • Severe heart failure
  • Severe pulmonary failure (SpO2<90%)
  • Kidney failure of IV-V degree
  • Infectious diseases in the acute phase (hepatitis C, hepatitis B, etc.)
  • Unstable hemodynamics, requiring correction with sympathomimetics
  • Terminal stage of incurable diseases
  • Acute stage of injuries or stroke
  • Pregnancy, pregnancy planning in the near future, breast feeding
  • Purulent joint diseases
  • Bone tuberculosis